BCL6-IN-6
Based on 1 Customer Validation
BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6 (BCL6). BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL).
For research use only. We do not sell to patients.
- Purity: 98.10%
- CAS No.: 2408882-54-0
- Formula: C27H31FN6O2S
- Molecular Weight:522.64
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Blood Cancer Compound Library
HY-L079
-
Transcription Factor-Targeted Library
HY-L090
-
Heterocyclic Compound Library
HY-L138
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
BCL6[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DOHH-2 | IC50 |
1 μM
Compound: 28
|
Antiproliferative activity against BCL-6 dependent human DOHH-2 cells by CCK-8 assay
Antiproliferative activity against BCL-6 dependent human DOHH-2 cells by CCK-8 assay
|
[PMID: 33844535] |
| DOHH-2 | IC50 |
1.21 μM
Compound: 14j
|
Antiproliferative activity against human DOHH2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human DOHH2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31895575] |
| Farage | IC50 |
1 μM
Compound: 28
|
Antiproliferative activity against BCL-6 dependent human Farage cells by CCK-8 assay
Antiproliferative activity against BCL-6 dependent human Farage cells by CCK-8 assay
|
[PMID: 33844535] |
| Farage | IC50 |
1.26 μM
Compound: 14j
|
Antiproliferative activity against human Farage cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human Farage cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31895575] |
| L02 | IC50 |
13.1 μM
Compound: 14j
|
Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31895575] |
| NCM460 | IC50 |
32.4 μM
Compound: 14j
|
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31895575] |
| OCI-Ly7 | IC50 |
1 μM
Compound: 28
|
Antiproliferative activity against BCL-6 dependent human OCILY7 cells by CCK-8 assay
Antiproliferative activity against BCL-6 dependent human OCILY7 cells by CCK-8 assay
|
[PMID: 33844535] |
| OCI-Ly7 | IC50 |
1.62 μM
Compound: 14j
|
Antiproliferative activity against human OCI-LY7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human OCI-LY7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31895575] |
| PNT1A | IC50 |
8.13 μM
Compound: 14j
|
Cytotoxicity against human PNT1A cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity against human PNT1A cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31895575] |
| SUD4 | IC50 |
0.92 μM
Compound: 14j
|
Antiproliferative activity against human SUDHL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human SUDHL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31895575] |
| SUD4 | IC50 |
1 μM
Compound: 28
|
Antiproliferative activity against BCL-6 dependent human SU-DHL-4 cells by CCK-8 assay
Antiproliferative activity against BCL-6 dependent human SU-DHL-4 cells by CCK-8 assay
|
[PMID: 33844535] |
| Toledo | IC50 |
3.25 μM
Compound: 14j
|
Antiproliferative activity against BCL6-negative human Toledo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against BCL6-negative human Toledo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 31895575] |
| Toledo | IC50 |
3.3 μM
Compound: 28
|
Antiproliferative activity against BCL-6 independent human Toledo cells by CCK-8 assay
Antiproliferative activity against BCL-6 independent human Toledo cells by CCK-8 assay
|
[PMID: 33844535] |
Chemical Information
-
CAS No. 2408882-54-0
-
Appearance Solid
-
Molecular Weight 522.64
-
Formula C27H31FN6O2S
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC=C(C2=CCCC2)S1)NC3=CC=C(NC4=NC(N5C[C@@H](C)N[C@@H](C)C5)=NC=C4F)C=C3OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : ≥ 4 mg/mL (7.65 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9134 mL | 9.5668 mL | 19.1336 mL | 47.8341 mL |
| 5 mM | 0.3827 mL | 1.9134 mL | 3.8267 mL | 9.5668 mL |
Powered by Bioz